Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-006427
Filing Date
2025-02-13
Accepted
2025-02-13 16:05:31
Documents
88
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1665115
2 ex31-1.htm EX-31.1 15572
3 ex31-2.htm EX-31.2 15390
4 ex32-1.htm EX-32.1 4880
5 ex32-2.htm EX-32.2 6879
  Complete submission text file 0001493152-25-006427.txt   8304516

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE eltp-20241231.xsd EX-101.SCH 55225
7 XBRL CALCULATION FILE eltp-20241231_cal.xml EX-101.CAL 87665
8 XBRL DEFINITION FILE eltp-20241231_def.xml EX-101.DEF 203538
9 XBRL LABEL FILE eltp-20241231_lab.xml EX-101.LAB 474805
10 XBRL PRESENTATION FILE eltp-20241231_pre.xml EX-101.PRE 375935
91 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1520549
Mailing Address 165 LUDLOW AVENUE NORTHVALE NJ 07647
Business Address 165 LUDLOW AVENUE NORTHVALE NJ 07647 2017502646
ELITE PHARMACEUTICALS INC /NV/ (Filer) CIK: 0001053369 (see all company filings)

EIN.: 223542636 | State of Incorp.: NJ | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-15697 | Film No.: 25620172
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)